The Global Intrauterine Devices Market was valued at USD 4 billion in 2024 and is estimated to grow at a CAGR of 10.9% to reach USD 11 billion by 2034.
The strong growth trajectory is driven by supportive regulatory policies, greater awareness among women about the diverse uses of IUDs, and the high incidence of unintended pregnancies. IUDs are increasingly acknowledged not only for their role in birth control but also for wider health applications, including the management of heavy menstrual bleeding, endometriosis, and perimenopausal symptoms. With the rise of educational initiatives, digital health platforms, and improved access to reproductive care information, women are now empowered to make more informed decisions about long-term contraceptive options. Healthcare professionals play a significant role by counseling patients on the safety, effectiveness, and additional health benefits of IUDs, which has boosted acceptance globally. Intrauterine devices are small, flexible, T-shaped contraceptive tools designed to provide reliable, reversible, and long-acting pregnancy prevention. Emerging innovations, such as iron-based non-hormonal devices, are being developed to minimize side effects and provide hormone-free solutions. These technological advancements are transforming the IUD landscape, enhancing choices for women, and reinforcing long-term market expansion.
The hormonal IUD segment held 53.8% share in 2024, supported by its effectiveness in preventing pregnancy and improving menstrual health. Hormonal IUDs, particularly those releasing levonorgestrel, are widely adopted for their long-lasting protection, low maintenance, and added therapeutic advantages, such as reduced menstrual bleeding and relief from endometriosis symptoms. Healthcare providers frequently recommend them due to their dual benefits, strengthening their dominance in the market.
The hospitals segment held 53.2% share in 2024 and is forecasted to generate USD 5.8 billion by 2034. Hospitals remain vital in delivering long-acting reversible contraception, as they provide access to skilled gynecologists and obstetricians for safe insertion procedures. The adoption of postpartum IUD insertion protocols in several regions has broadened access and contributed to a decline in unplanned pregnancies, particularly in areas with robust maternal healthcare systems.
U.S. Intrauterine Devices Market was valued at USD 1.44 billion in 2024 and is estimated to grow at a CAGR of 10.3% between 2025 and 2034. Increased public health initiatives and awareness campaigns have encouraged the use of IUDs as a safe, effective, and convenient contraceptive option. Growing preference for long-acting reversible contraception over short-term alternatives, such as daily pills, has further accelerated adoption across diverse demographics in the U.S. and Canada.
Prominent companies active in the Intrauterine Devices Industry include MONA LISA, Meril, Sebela Pharmaceuticals, DKT, PREGNA, SMB, AbbVie, Prosan, GIMA, Bayer, Medicines360, eurogine, GYNO CARE, CooperSurgical, HLL Lifecare Limited, and others. To strengthen their foothold in the intrauterine devices market, leading companies are focusing on expanding product portfolios with both hormonal and non-hormonal options, including the development of innovative materials designed to minimize side effects and improve user comfort. Strategic collaborations with healthcare organizations and government programs are being pursued to broaden access and adoption rates. Many players are also investing in awareness campaigns to educate women on the benefits of IUDs beyond contraception, such as menstrual health management.
This product will be delivered within 2-4 business days.
The strong growth trajectory is driven by supportive regulatory policies, greater awareness among women about the diverse uses of IUDs, and the high incidence of unintended pregnancies. IUDs are increasingly acknowledged not only for their role in birth control but also for wider health applications, including the management of heavy menstrual bleeding, endometriosis, and perimenopausal symptoms. With the rise of educational initiatives, digital health platforms, and improved access to reproductive care information, women are now empowered to make more informed decisions about long-term contraceptive options. Healthcare professionals play a significant role by counseling patients on the safety, effectiveness, and additional health benefits of IUDs, which has boosted acceptance globally. Intrauterine devices are small, flexible, T-shaped contraceptive tools designed to provide reliable, reversible, and long-acting pregnancy prevention. Emerging innovations, such as iron-based non-hormonal devices, are being developed to minimize side effects and provide hormone-free solutions. These technological advancements are transforming the IUD landscape, enhancing choices for women, and reinforcing long-term market expansion.
The hormonal IUD segment held 53.8% share in 2024, supported by its effectiveness in preventing pregnancy and improving menstrual health. Hormonal IUDs, particularly those releasing levonorgestrel, are widely adopted for their long-lasting protection, low maintenance, and added therapeutic advantages, such as reduced menstrual bleeding and relief from endometriosis symptoms. Healthcare providers frequently recommend them due to their dual benefits, strengthening their dominance in the market.
The hospitals segment held 53.2% share in 2024 and is forecasted to generate USD 5.8 billion by 2034. Hospitals remain vital in delivering long-acting reversible contraception, as they provide access to skilled gynecologists and obstetricians for safe insertion procedures. The adoption of postpartum IUD insertion protocols in several regions has broadened access and contributed to a decline in unplanned pregnancies, particularly in areas with robust maternal healthcare systems.
U.S. Intrauterine Devices Market was valued at USD 1.44 billion in 2024 and is estimated to grow at a CAGR of 10.3% between 2025 and 2034. Increased public health initiatives and awareness campaigns have encouraged the use of IUDs as a safe, effective, and convenient contraceptive option. Growing preference for long-acting reversible contraception over short-term alternatives, such as daily pills, has further accelerated adoption across diverse demographics in the U.S. and Canada.
Prominent companies active in the Intrauterine Devices Industry include MONA LISA, Meril, Sebela Pharmaceuticals, DKT, PREGNA, SMB, AbbVie, Prosan, GIMA, Bayer, Medicines360, eurogine, GYNO CARE, CooperSurgical, HLL Lifecare Limited, and others. To strengthen their foothold in the intrauterine devices market, leading companies are focusing on expanding product portfolios with both hormonal and non-hormonal options, including the development of innovative materials designed to minimize side effects and improve user comfort. Strategic collaborations with healthcare organizations and government programs are being pursued to broaden access and adoption rates. Many players are also investing in awareness campaigns to educate women on the benefits of IUDs beyond contraception, such as menstrual health management.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Age Group, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The key companies profiled in this Intrauterine Devices market report include:- AbbVie
- Bayer
- CooperSurgical
- DKT
- eurogine
- GIMA
- GYNO CARE
- HLL Lifecare Limited
- Medicines360
- Meril
- MONA LISA
- PREGNA
- Prosan
- Sebela Pharmaceuticals
- SMB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 4 Billion |
| Forecasted Market Value ( USD | $ 11 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
